English  |  正體中文  |  简体中文  |  Post-Print筆數 : 11 |  Items with full text/Total items : 88613/118155 (75%)
Visitors : 23481388      Online Users : 245
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    政大機構典藏 > 理學院 > 心理學系 > 期刊論文 >  Item 140.119/80625
    Please use this identifier to cite or link to this item: http://nccur.lib.nccu.edu.tw/handle/140.119/80625

    Title: Hepatitis B virus: new therapeutic perspectives
    Authors: Lin, Chih-Lin
    Yang, Hung-Chih
    Kao, Jia-Horng
    Contributors: 心理系
    Date: 2016-01
    Issue Date: 2016-01-15 15:54:22 (UTC+8)
    Abstract: Current antiviral therapies have dramatically improved the long-term outcomes of patients with chronic hepatitis B virus ( HBV) infection. Both interferon ( IFN) and nucleos(t)ide analogue ( NA) treatments have been shown to reduce the progression of liver disease in chronic hepatitis B ( CHB) patients. However, persistent covalently closed circular DNA (ccc DNA) can result in a viral relapse after discontinuation of antiviral treatment. On the basis of extensive research on the HBV lifecycle and virus-host interactions, several new agents focusing on viral and host targets are under development to cure HBV. New polymerase inhibitors, tenofovir alafenamide and besifovir provide effective and safer treatment for CHB patients. Agents targeting ccc DNA, such as engineered site-specific nucleases and RNA interference therapeutics could eliminate ccc DNA or silence ccc DNA transcription. Inhibitors of HBV nucleocapsid assembly suppress capsid formation and prevent synthesis of HBV DNA. The HBV entry inhibitor, Myrcludex-B, has been shown to effectively inhibit amplification of ccc DNA as well as the spread of intrahepatic infection. Agents targeting host factors that enhance innate and adaptive immune responses, including the lymphotoxin-β receptor agonist, toll-like receptor agonist, immune checkpoint inhibitors and adenovirus-based therapeutic vaccine, could play a critical role in the elimination of HBV-infected cells. With all of these promising approaches, we hope to reach the ultimate goal of a cure to HBV in the near future.
    Relation: Liver International, 36, 85-92
    Data Type: article
    DOI 連結: http://dx.doi.org/10.1111/liv.13003
    DOI: 10.1111/liv.13003
    Appears in Collections:[心理學系] 期刊論文

    Files in This Item:

    File Description SizeFormat
    85-92.pdf1261KbAdobe PDF396View/Open

    All items in 政大典藏 are protected by copyright, with all rights reserved.

    社群 sharing

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback